Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SWEDBANK AB - A SHARES. We currently have 3 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
SWEDBANK AB - A SHARES
SWEDBANK AB - A SHARES
Net interest income definitely picking up...
02 Feb 17
Swedbank released its Q4 16 earnings results this morning. Total income at SEK10.2bn is 1% higher than expectations while total expenses were 1.3% higher than expected at SEK4.4bn. Loan losses on their side are roughly in line with expectations at SEK593m (SEK649m taking into account the impairment of tangible and intangible assets). All in all, profit before tax is slightly higher than expected (+0.5%) at SEK5.15bn. The CET1 ratio at 25% is 100bp higher qoq but management is still considering that there is no excess capital available.
Boring banking is still supporting shareholders...
21 Jul 16
Total revenues (once adjusted for one-off gains related to VISA Europe) are 2.5% higher than expectations (at SEK9.75bn), driven by all types of revenues (reported total income at SEK11.87bn). While expenses are in line with expectations, loan losses are above forecasts due to individual provisions in the oil-related exposures. CET1 ratio is 10bp lower than last quarter at 23%. Like Nordea yesterday, Swedbank disclosed its potential future requirements (SREP in September) which will be around 20.3%.
Mixed earnings results...
03 Feb 16
Swedbank announced its Q415 earnings release this morning: Revenues are in line with expectations (good news being net interest income and net fees and commissions are in line as well). With expenses in line but loan losses much higher than expected, profit before taxe came short of expectations (-3.5%).
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.